This drug is used as a treatment of Covid-19, which is given as a oral intake.
“The company has received a licence from Defence Research and Development Organisation (DRDO) to Manufacture and Market of ‘2-Deoxy-D-Glucose’ as approved medication for the treatment of COVID-19 patients,” Bajaj Healthcare said in a regulatory filing.
Shares of Bajaj Healthcare suged 11 per cent to Rs 1009.80 on Thursday. However, the counter was trading at Rs 968 at 10.30 am. BSE Sensex was trading 52,920.01, 134.75 point or 0.25 per cent lower at the same time. It settled at Rs 911.10 on Wednesday.
The 2-DG Ccovid-19 control and treatment drug has been developed by the DRDO laboratory’s Institute of Nuclear Medicine and Allied Sciences (INMAS), in collaboration with the pharma major Dr Reddy’s Laboratories.
It has already received emergency approval from the Drugs Controller General of India (DCGI) for use on Covid-19 patients in the country. The drug comes in powder form and retails at Rs 990 per sachet.
Bajaj Healthcare has more than doubled investors’ wealth in the year 2021 so far. The counter has delivered over 24 per cent return in the last one month.
Bajaj Healthcare was recently listed on NSE. The board of Bajaj Healthcare on Monday approved the listing on the National Stock Exchange of India. The company has about 1.38 crore outstanding shares of Rs 10 each.
